Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 28, 2008
Overview: Greatbatch is a developer and manufacturer of critical products for medical devices (cardiac rhythm management, neurostimulation, orthopedics) and electrochemical cells for industrial applications. The quarter was defined by significant M&A activity, including the acquisitions of P Medical Holding SA ("Precimed") and the DePuy Orthopedics Chaumont Facility, aimed at diversifying revenue and expanding into the orthopedic market.
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Sales | $122,154 | $76,860 |
| Operating Income (Loss) | $(4,140) | $10,606 |
| Net Income (Loss) | $(3,374) | $10,669 |
| Diluted EPS | $(0.15) | $0.43 |
| Operating Margin | -3.4% | 13.8% |
| Net Margin | -2.8% | 13.9% |
| Cash and Cash Equivalents | $14,307 | $33,473 |
| Total Debt (Current + Long-term) | $360,672 | $241,198 |
| Working Capital | $132,823 | $116,816 |
Cash Flow: Net cash provided by operating activities was $3.05 million. Net cash used in investing activities was $106.9 million, primarily due to acquisitions. Net cash provided by financing activities was $84.5 million, driven by $117 million in borrowings under the revolving line of credit.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 59% to $122.2 million. This includes $44.3 million from acquisitions in 2007 and 2008. On an organic basis, sales declined 11% due to lower volumes in coated components, feedthroughs, and capacitors.
- Profitability Decline: The company reported a net loss of $3.4 million compared to a net income of $10.7 million in the prior year. This reversal was driven by:
- Acquisition Costs: $2.2 million in acquired in-process research and development (IPR&D) expensed immediately and $6.4 million in inventory step-up amortization.
- Higher Expenses: Cost of sales increased 98% and SG&A increased 83%, largely due to the inclusion of acquired entities with higher cost structures and integration costs.
- Interest Expense: Increased 200% to $3.4 million due to new debt incurred to fund acquisitions.
- Balance Sheet: Total assets grew to $814.6 million from $663.9 million. Goodwill increased by $50.3 million due to acquisitions. Long-term debt increased significantly as the company utilized its revolving credit facility to fund the $80.5 million Precimed acquisition and the $27.9 million Chaumont Facility acquisition.
Guidance, Outlook, and Risks
- Management Commentary: Management views the acquisitions as successful in diversifying revenue, reducing Cardiac Rhythm Management (CRM) market concentration from ~85% to below 50%. They anticipate annual cost savings of $2.5–$3.1 million from the Carson City/Tijuana consolidation and $5.0–$6.0 million from the Columbia/Tijuana consolidation once completed.
- Outlook: The company expects the effective tax rate to be approximately 39% for 2008. Capital spending for the remainder of 2008 is expected to total approximately $45 million. Management does not anticipate making principal payments on the revolving line of credit within the next twelve months.
- Risks and Contingencies:
- Integration Risk: Ongoing integration of seven acquisitions completed since mid-2007, with continued severance and integration costs expected through 2009.
- Legal Proceedings: A patent infringement lawsuit filed by Pressure Products Medical Supplies, Inc. against subsidiary Enpath regarding FlowGuard products is expected to go to trial in Q2 2008. Potential loss is indeterminable but could impact sales of affected products.
- Customer Concentration: Four customers accounted for 55% of sales in Q1 2008 (down from 69% in Q1 2007).
- Foreign Currency: Increased exposure to Swiss Francs, British Pounds, and Euros following acquisitions. A 10% change in the USD could impact net sales by approximately $10 million.
Investor Verification Checklist
- Acquisition Valuation: Verify the final purchase price allocation for Precimed and the Chaumont Facility, specifically the valuation of goodwill and intangible assets, which are currently preliminary.
- Organic Growth: Confirm the sustainability of the 11% organic sales decline in legacy IMC products (capacitors, feedthroughs) and the timeline for recovery.
- Debt Covenants: Monitor compliance with credit facility covenants, specifically the adjusted EBITDA to interest expense ratio (minimum 3.00:1) and total leverage ratio (maximum 5.00:1), given the recent increase in debt load.
- Legal Exposure: Track the outcome of the Enpath patent infringement litigation, which could result in injunctions or damages affecting the FlowGuard product line.
- Cost Synergies: Assess the realization of projected cost savings ($7.5M–$9.1M annually) from facility consolidations and "Lean" manufacturing initiatives in acquired businesses.